Literature DB >> 25398832

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.

Philippe Rodon1, Cyrille Hulin2, Brigitte Pegourie3, Mourad Tiab4, Bruno Anglaret5, Lotfi Benboubker6, Henry Jardel7, Olivier Decaux8, Brigitte Kolb9, Murielle Roussel10, Laurent Garderet11, Xavier Leleu12, Olivier Fitoussi13, Carine Chaleteix14, Philippe Casassus15, Pascal Lenain16, Bruno Royer17, Anne Banos18, Riad Benramdane19, Pascale Cony-Makhoul20, Mamoun Dib21, Jean Fontan22, Anne-Marie Stoppa23, Catherine Traullé24, Jean-Pierre Vilque25, Marie-Odile Pétillon12, Claire Mathiot26, Thomas Dejoie27, Hervé Avet-Loiseau10, Philippe Moreau27.   

Abstract

Entities:  

Keywords:  bendamustine; elderly; multiple myeloma; relapse

Mesh：

Substances：

Year:  2014        PMID： 25398832      PMCID： PMC4803137          DOI： 10.3324/haematol.2014.110890

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  The era of combination therapy in myeloma.

Authors:  Sagar Lonial; Jonathan L Kaufman
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544

2.  Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.

Authors:  Heinz Ludwig; Hedwig Kasparu; Clemens Leitgeb; Elisabeth Rauch; Werner Linkesch; Niklas Zojer; Richard Greil; Adelheid Seebacher; Ludek Pour; Adalbert Weißmann; Zdenek Adam
Journal:  Blood       Date:  2013-11-13       Impact factor: 22.113

3.  Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.

Authors:  Peter M Fayers; Antonio Palumbo; Cyrille Hulin; Anders Waage; Pierre Wijermans; Meral Beksaç; Sara Bringhen; Jean-Yves Mary; Peter Gimsing; Fabian Termorshuizen; Rauf Haznedar; Tommaso Caravita; Philippe Moreau; Ingemar Turesson; Pellegrino Musto; Lotfi Benboubker; Martijn Schaafsma; Pieter Sonneveld; Thierry Facon
Journal:  Blood       Date:  2011-06-13       Impact factor: 22.113

4.  Bendamustine: the remedy that came in from the cold.

Authors:  Suzanne Lentzsch
Journal:  Blood       Date:  2014-02-13       Impact factor: 22.113

5.  Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

Authors:  Lotfi Benboubker; Meletios A Dimopoulos; Angela Dispenzieri; John Catalano; Andrew R Belch; Michele Cavo; Antonello Pinto; Katja Weisel; Heinz Ludwig; Nizar Bahlis; Anne Banos; Mourad Tiab; Michel Delforge; Jamie Cavenagh; Catarina Geraldes; Je-Jung Lee; Christine Chen; Albert Oriol; Javier de la Rubia; Lugui Qiu; Darrell J White; Daniel Binder; Kenneth Anderson; Jean-Paul Fermand; Philippe Moreau; Michel Attal; Robert Knight; Guang Chen; Jason Van Oostendorp; Christian Jacques; Annette Ervin-Haynes; Hervé Avet-Loiseau; Cyrille Hulin; Thierry Facon
Journal:  N Engl J Med       Date:  2014-09-04       Impact factor: 91.245

6.  Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program.

Authors:  G Damaj; F Malard; C Hulin; D Caillot; R Garidi; B Royer; G Marit; A M Stoppa; A Banos; N Morineau; P Moreau; O Fitoussi; M Tiab; P Moreau
Journal:  Leuk Lymphoma       Date:  2011-11-25

7.  International uniform response criteria for multiple myeloma.

Authors:  B G M Durie; J-L Harousseau; J S Miguel; J Bladé; B Barlogie; K Anderson; M Gertz; M Dimopoulos; J Westin; P Sonneveld; H Ludwig; G Gahrton; M Beksac; J Crowley; A Belch; M Boccadaro; M Cavo; I Turesson; D Joshua; D Vesole; R Kyle; R Alexanian; G Tricot; M Attal; G Merlini; R Powles; P Richardson; K Shimizu; P Tosi; G Morgan; S V Rajkumar
Journal:  Leukemia       Date:  2006-07-20       Impact factor: 11.528

8.  A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Authors:  S Jagannath; B Barlogie; J Berenson; D Siegel; D Irwin; P G Richardson; R Niesvizky; R Alexanian; S A Limentani; M Alsina; J Adams; M Kauffman; D-L Esseltine; D P Schenkein; K C Anderson
Journal:  Br J Haematol       Date:  2004-10       Impact factor: 6.998

9.  Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Authors:  Jesús F San-Miguel; Vânia T M Hungria; Sung-Soo Yoon; Meral Beksac; Meletios Athanasios Dimopoulos; Ashraf Elghandour; Wieslaw Wiktor Jedrzejczak; Andreas Günther; Thanyaphong Na Nakorn; Noppadol Siritanaratkul; Paolo Corradini; Suporn Chuncharunee; Je-Jung Lee; Robert L Schlossman; Tatiana Shelekhova; Kwee Yong; Daryl Tan; Tontanai Numbenjapon; Jamie D Cavenagh; Jian Hou; Richard LeBlanc; Hareth Nahi; Lugui Qiu; Hans Salwender; Stefano Pulini; Philippe Moreau; Krzysztof Warzocha; Darrell White; Joan Bladé; WenMing Chen; Javier de la Rubia; Peter Gimsing; Sagar Lonial; Jonathan L Kaufman; Enrique M Ocio; Ljupco Veskovski; Sang Kyun Sohn; Ming-Chung Wang; Jae Hoon Lee; Hermann Einsele; Monika Sopala; Claudia Corrado; Bourras-Rezki Bengoudifa; Florence Binlich; Paul G Richardson
Journal:  Lancet Oncol       Date:  2014-09-18       Impact factor: 41.316

10.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Authors:  Jesús F San Miguel; Rudolf Schlag; Nuriet K Khuageva; Meletios A Dimopoulos; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Maria T Petrucci; Antonio Palumbo; Olga S Samoilova; Anna Dmoszynska; Kudrat M Abdulkadyrov; Rik Schots; Bin Jiang; Maria-Victoria Mateos; Kenneth C Anderson; Dixie L Esseltine; Kevin Liu; Andrew Cakana; Helgi van de Velde; Paul G Richardson
Journal:  N Engl J Med       Date:  2008-08-28       Impact factor: 91.245
View more
  15 in total

1.  Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management

Authors: 
Journal:  Am J Hematol       Date:  2018-08-16       Impact factor: 10.047

2.  Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma.

Authors:  Elisabeth Stöhr; Frederic Carsten Schmeel; Leonard Christopher Schmeel; Mathias Hänel; Ingo G H Schmidt-Wolf
Journal:  J Cancer Res Clin Oncol       Date:  2015-07-09       Impact factor: 4.553

Review 3.  Novel Agents in Multiple Myeloma.

Authors:  Raphaël Szalat; Nikhil C Munshi
Journal:  Cancer J       Date:  2019 Jan/Feb       Impact factor: 3.360

Review 4.  The Diagnosis and Treatment of Multiple Myeloma.

Authors:  Christian Gerecke; Stephan Fuhrmann; Susanne Strifler; Martin Schmidt-Hieber; Hermann Einsele; Stefan Knop
Journal:  Dtsch Arztebl Int       Date:  2016-07-11       Impact factor: 5.594

5.  Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.

Authors:  S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2022-05-23       Impact factor: 13.265

6.  Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure.

Authors:  Wolfram Pönisch; Barbara Moll; Malvina Bourgeois; Marc Andrea; Thomas Schliwa; Simone Heyn; Marion Schmalfeld; Thomas Edelmann; Cornelia Becker; Franz Albert Hoffmann; Andreas Schwarzer; Ute Kreibich; Matthias Egert; Runa Stiegler; Rainer Krahl; Yvonne Remane; Anette Bachmann; Tom Lindner; Lorenz Weidhase; Sirak Petros; Stefan Fricke; Vladan Vucinic; Haifa Al Ali; Dietger Niederwieser
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-18       Impact factor: 4.553

7.  Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.

Authors:  María-Victoria Mateos; Albert Oriol; Laura Rosiñol; Felipe de Arriba; Noemí Puig; Jesús Martín; Joaquín Martínez-López; María Asunción Echeveste; Josep Sarrá; Enrique Ocio; Gemma Ramírez; Rafael Martínez; Luis Palomera; Angel Payer; Rebeca Iglesias; Javier de la Rubia; Adrian Alegre; Ana Isabel Chinea; Joan Bladé; Juan José Lahuerta; Jesús-F San Miguel
Journal:  Haematologica       Date:  2015-04-24       Impact factor: 9.941

Review 8.  Treatment of relapsed and refractory multiple myeloma.

Authors:  Pieter Sonneveld; Annemiek Broijl
Journal:  Haematologica       Date:  2016-04       Impact factor: 9.941

9.  Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.

Authors:  Wolfram Pönisch; Malvina Bourgeois; Barbara Moll; Simone Heyn; Nadja Jäkel; Ina Wagner; Robert Rohrberg; Hans-Jürgen Hurtz; Marion Schmalfeld; Michael Aßmann; Thomas Edelmann; Martin Mohren; Franz Albert Hoffmann; Cornelia Becker; Andreas Schwarzer; Uta Schönfelder; Thomas Zehrfeld; Gerald Hensel; Kerstin Löschcke; Rainer Krahl; Haifa Al Ali; Dietger Niederwieser
Journal:  J Cancer Res Clin Oncol       Date:  2012-11-25       Impact factor: 4.553

Review 10.  Novel agents in the treatment of multiple myeloma: a review about the future.

Authors:  Leonard Naymagon; Maher Abdul-Hay
Journal:  J Hematol Oncol       Date:  2016-06-30       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.